Canada Markets closed

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.90000.0000 (0.00%)
At close: 10:49AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.9000
Open0.8800
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range0.8800 - 0.9000
52 Week Range0.7020 - 3.2500
Volume416
Avg. Volume19,268
Market Cap43.624M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.0890
Earnings DateNov. 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Emmaus Life Sciences Announces Informational Stockholders Meeting

    \--Meeting Will be Open to the Public--TORRANCE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease  treatment, announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations, as well as the status of the filing of Emmaus’ Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the first two quarters of 2020 and related matters. The informational meeting will be held virtually on September 17, 2020, at 3:00 P.M., Pacific Time (unless postponed to a later date).  The meeting will be held solely via the Internet and can be accessed at www.virtualshareholdermeeting.com/EMMA2020, where stockholders and other interested parties can listen to the live proceedings.  The meeting is for informational purposes only.  Stockholders are not being asked to vote or take action with respect to any matter.  Although the informational meeting will be open to the public, only stockholders of record at the close of business on August 17, 2020, the record date for the meeting, are entitled to submit questions at the meeting. About Emmaus Life Sciences Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.  For more information, please visit www.emmausmedical.com.Company Contact: Investor Relations Contact: Emmaus Life Sciences, Inc.LifeSci Advisors Willis C. Lee Bruce Mackle Chief Operating Officer (929) 469-3859 (310) 214-0065   bmackle@lifesciadvisors.com wlee@emmauslifesciences.com

  • GlobeNewswire

    UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

    TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia. This follows Emmaus’ announcement that the SFDA had granted Endari® a priority review designation as part of its program to expedite the review of drugs that are expected to have a significant impact on the treatment of a disease with unmet medical need. Endari®, Emmaus’ prescription grade L-glutamine oral powder, is approved by the United States FDA to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari® can currently be prescribed in Saudi Arabia on a named patient basis and will continue to be available on that basis during the review and approval process with the SFDA. Emmaus estimates that there are approximately 225,000 sickle cell disease patients that could potentially be treated with Endari® in the Middle East and North Africa (MENA) region. Saudi Arabia has the highest prevalence of sickle cell disease in the MENA region with an estimated 100,000 treatable patients.Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, stated, “We are pleased with the progress we continue to make in the MENA region and look forward to the SFDA’s review of our MA application. With the opening of our office in Dubai, expedited review previously granted by the SFDA and now the submission of our MA application, we are gratified to be in a position to improve the lives of the sickle cell disease patients in Saudi Arabia.”George Sekulich, Senior Vice President of Global Commercialization of Emmaus, added, “Emmaus is excited to bring Endari® to Saudi Arabia and will continue to enhance our partnerships with the hematologists and patient advocacy groups across the MENA region to serve the patients and their families afflicted with sickle cell disease in the best way possible.”About Emmaus Life Sciences Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. For more information, please visit www.emmausmedical.com.About Endari® (L-glutamine oral powder) Indication - Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.Important Safety Information The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.About Sickle Cell Disease Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to organ damage, stroke, pulmonary complications, skin ulceration, infection and a variety of other adverse outcomes. Sickle cell disease is a significant unmet medical need, affecting approximately one hundred thousand patients in the U.S. and millions worldwide, the majority of which are of African descent. An estimated 1-in-365 African American children are born with sickle cell disease.Forward-looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding patient access to Endari®. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including uncertainties relating to possible future marketing approval in Saudi Arabia and the MENA region and Emmaus’ working capital and ability to carry on its existing operations and obtain needed financing and other factors previously disclosed in the company’s reports filed with the Securities and Exchange Commission, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law. Company Contact:Investor Relations Contact: Emmaus Life Sciences, Inc.LifeSci Advisors Joseph (Jay) C. Sherwood IIIBruce Mackle Chief Financial Officer(929) 469-3859 (310) 214-0065, Ext. 3005bmackle@lifesciadvisors.com  jsherwood@emmauslifesciences.com

  • GlobeNewswire

    Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

    TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia. This follows Emmaus’ announcement that the SFDA had granted Endari® a priority review designation as part of its program to expedite the review of drugs that are expected to have a significant impact on the treatment of a disease with unmet medical need.  Endari®, Emmaus’ prescription grade L-glutamine oral powder, is approved by the United States FDA and the Israeli Ministry of Health to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari® can currently be prescribed in Saudi Arabia on a named patient basis and will continue to be available on that basis during the review and approval process with the SFDA.  Emmaus estimates that there are approximately 225,000 sickle cell disease patients that could potentially be treated with Endari® in the Middle East and North Africa (MENA) region.  Saudi Arabia has the highest prevalence of sickle cell disease in the MENA region with an estimated 100,000 treatable patients.Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, stated, “We are pleased with the progress we continue to make in the MENA region and look forward to the SFDA’s review of our MA application. With the opening of our office in Dubai, expedited review previously granted by the SFDA and now the submission of our MA application, we are gratified to be in a position to improve the lives of the sickle cell disease patients in Saudi Arabia.”George Sekulich, Senior Vice President of Global Commercialization of Emmaus, added, “Emmaus is excited to bring Endari® to Saudi Arabia and will continue to enhance our partnerships with the hematologists and patient advocacy groups across the MENA region to serve the patients and their families afflicted with sickle cell disease in the best way possible.”About Emmaus Life Sciences Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.  For more information, please visit www.emmausmedical.com.About Endari® (L-glutamine oral powder) Indication - Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.Important Safety Information The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.About Sickle Cell Disease Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded.  Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels.  Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation.  These events may lead to organ damage, stroke, pulmonary complications, skin ulceration, infection and a variety of other adverse outcomes.  Sickle cell disease is a significant unmet medical need, affecting approximately one hundred thousand patients in the U.S. and millions worldwide, the majority of which are of African descent.   An estimated 1-in-365 African American children are born with sickle cell disease.Forward-looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding patient access to Endari®. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including uncertainties relating to possible future marketing approval in Saudi Arabia and the MENA region and Emmaus’ working capital and ability to carry on its existing operations and obtain needed financing and other factors previously disclosed in the company’s reports filed with the Securities and Exchange Commission, and actual results may differ materially.  Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law. Company Contact:Investor Relations Contact: Emmaus Life Sciences, Inc.LifeSci Advisors Joseph (Jay) C. Sherwood IIIBruce Mackle Chief Financial Officer(929) 469-3859 (310) 214-0065, Ext. 3005bmackle@lifesciadvisors.com jsherwood@emmauslifesciences.com